Press Detail

News: Biotest AG: Biotest AG shareholders accept voluntary public tender offer by CREAT Group

News: Biotest AG / Key word(s): Offer
Biotest AG: Biotest AG shareholders accept voluntary public tender offer by

14.06.2017 / 16:05
The issuer is solely responsible for the content of this announcement.


Biotest AG shareholders accept voluntary public tender offer by CREAT Group

Dreieich, 14 June, 2017. The shareholders of Biotest AG have accepted the
voluntary public tender offer by Tiancheng (Germany) Pharmaceutical Holdings
AG, the bidding company controlled by CREAT Group, by fulfilling the minimum
acceptance condition of 75 percent of Biotest ordinary shares outstanding.
This represents a major step in the successful completion of this
transaction. The final completion of the transaction is still subject to
merger control in Turkey as well as regulatory approvals.

Dr. Bernhard Ehmer, CEO of Biotest AG: "We are pleased that our shareholders
have accepted this offer from CREAT Group. We now have a strong partner that
will strengthen our Biotest Next Level strategy and support investments in
the development of new products and the expansion of our international

According to the German Securities Acquisition and Takeover Act (WpÜG),
shareholders of Biotest AG who have not tendered their shares can still
accept the offer by tendering their shares during the additional acceptance
period, which is expected to begin on 22 June, 2017 and will end on 5 July,
2017 at midnight CET (24:00 CET).

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and markets
immunoglobulins, coagulation factors and albumins based on human blood
plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus which
are produced by recombinant technologies. Biotest has more than 2,500
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406

PR contact
Dirk Neumüller
phone: +49-6103-801-269

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany,

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich,

This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and assumes
no obligation to do so.

14.06.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange

End of News DGAP News Service

583107 14.06.2017